prematurity and intensive care unit (ICU) admission are the most common risk factors in neonates, and hematologic malignancy and neutropenia are frequent candidemia risk factors in noninfant children [3, 4] . In contrast, diabetes, renal disease, hemodialysis, and abdominal surgery are the most common risk factors for candidemia in adults [5] . Candida species are distributed differentially according to age, especially in neonates, in whom C albicans and C parapsilosis predominate [6] , and adults, in whom C albicans and C glabrata are the most common species [2] . Given these differences, updating our understanding of candidemia epidemiology in children is particularly important.
Several preventive strategies for decreasing candidemia rates among pediatric groups at high risk have been recommended. For neonates, these strategies include CVC care bundles, empiric antifungal treatment, and antifungal prophylaxis [7] . The 2009 and 2016 Infectious Diseases Society of America clinical practice guidelines for the management of candidiasis recommend antifungal prophylaxis in neonates who weigh less than 1000 g and are in a neonatal ICU (NICU) with a high candidemia rate [8, 9] . Recent reports documented a decline in candidemia rates among infants aged <1 year [2, 10] . Prophylaxis has not been associated with increased antifungal drug resistance in single-center studies [11] [12] [13] . There are also new guidelines for antifungal prophylaxis in children with cancer and those who have undergone a stem cell transplant [14] . A need exists for population-based studies to examine changes in the incidence of candidemia, Candida species distribution, and antifungal susceptibility to understand the effects that antifungal prophylaxis and other practices might have on Candida epidemiology in children.
Here we describe neonatal and pediatric candidemia cases detected through active population-based laboratory surveillance in 4 locations in the United States between 2009 and 2015 and document trends in incidence, species distribution, antifungal resistance.
MATERIALS AND METHODS

Surveillance Population
The Centers for Disease Control and Prevention (CDC) Emerging Infections Program conducts active population-based surveillance for candidemia in 4 metropolitan areas: Atlanta, Georgia (started in March 2008), Baltimore City and Baltimore County, Maryland (started in June 2008), the tricounty region of Portland, Oregon (started in January 2011), and Knoxville, Tennessee (started in January 2011); the combined surveillance population is approximately 8 million persons.
Case Definitions
A candidemia case was defined as a case in which a positive Candida species blood culture result was found for a surveillance-area resident between surveillance initiation and December 31, 2015, and occurred at least 30 days from any other blood culture that was positive for Candida species in the same resident. The age groups that we used for patients at the time of the first positive Candida blood culture result were 0 to 30 days (neonates), 31 to 364 days (nonneonate infants), 0 to 364 days (infants), 1 to 19 years (noninfant children), and >19 years (adults). Adult cases were excluded from this analysis.
Data and Isolate Collection
Clinical, reference, and commercial laboratories that serve the population in the surveillance catchment areas were recruited to participate in the surveillance program and report cases of candidemia to the local surveillance officer. Surveillance officers, once notified of a positive Candida blood culture result, applied the surveillance case definition to determine case status and completed a standardized case-report form to abstract demographic and clinical data from the medical record. The corresponding Candida isolate was sent to the CDC for species confirmation and antifungal-susceptibility testing. Surveillance officers conducted periodic audits of participating laboratories to ensure that all cases of candidemia had been captured.
Isolate Identification and Antifungal-Susceptibility Testing
At the CDC fungal reference laboratory, Candida species were confirmed using a Luminex assay (Luminex Corporation, Austin, Texas) or DNA sequencing of the D1/D2 subunit of the 28S ribosomal DNA [15] until 2014; matrix-assisted laser desorption-ionization time of flight was used for species identification between 2014 and 2015. CDC-confirmed species are reported; if no isolate was received by the CDC, local laboratory species identification was reported (19 cases). Antifungalsusceptibility testing was performed at the CDC by using broth microdilution with fluconazole, anidulafungin, caspofungin, and micafungin according to the Clinical and Laboratory Standards Institute M27-A3 document guidelines [14] and using frozen Roswell Park Memorial Institute microbroth trays with no indicator dye that were custom manufactured by TREK Diagnostics (Cleveland, Ohio) . Results were read after 24 hours, and the minimum inhibitory concentration (the lowest concentration of drug that caused a significant decrease in growth compared with that of the control well) was determined. Each isolate was categorized as susceptible, intermediate, or resistant to echinocandins and fluconazole, based on the 2012 Clinical and Laboratory Standards Institute M27-S4 species-specific breakpoints [16] .
Incidence Calculations and Statistical Methods
Annual overall and race-and sex-specific incidence rates for infants and noninfant children at each surveillance site and all participating sites combined were calculated using denominators for corresponding years (2009) (2010) (2011) (2012) (2013) (2014) (2015) from the US Census Bureau. The incidence rates for neonates were calculated using birth data from the National Center for Health Statistics [17] . Incidence rates for infants (ages 0-364 days) included neonates (0-30 days) because neonates cannot be separated from nonneonate infants (31-364 days) in US Census data. Statistical analyses were conducted using SAS 9.4 software (SAS Institute, Inc., Cary, North Carolina).
Human Subjects
The CDC conducted ethical review of this surveillance project and deemed it a nonresearch activity. This activity was also evaluated individually at each location and was deemed either a public health assessment and a nonresearch activity or human subject research and approved by the local hospital review boards. 
RESULTS
Demographic Characteristics and Incidence of Candidemia
We identified 307 pediatric candidemia cases among 268 children between 2009 and 2015, 90 (29%) among neonates, 53 (17%) among nonneonate infants, and 164 (53%) among noninfant children (Table 1) ; 182 (59%) cases involved male patients, and 66% cases involved black patients (among those for whom race data were available). The median ages of those (2) 38 (28) 39 (14) Leukemia/lymphoma/multiple myeloma 0 (0) 0 (0) 20 (15) 20 (7) Solid organ malignancy
Other cancer 0 (0) 1 (2) 12 (9) 13 (5) Solid organ transplant (4) 18 (23) 20 (14) Previous candidemia (n [%]) 0 (0) 7 (13) 32 (20) 39 ( (20) 15 (28) 30 (18) 63 (21) Fluconazole 15 (17) 6 (11) 13 (8) 34 (11) Amphotericin B 3 (3) 5 (9) 1 (1) 9 (3) Echinocandin 0 (0) 1 (2) 10 (6) 11 (4) Received with candidemia at the time of diagnosis were 11.5 days (interquartile range [IQR], 7-16 days) for neonates, 2.7 months (IQR, 1.6-7.9 months) for nonneonate infants, and 5.8 years (IQR, 2.5-14.3 years) for noninfant children.
Among neonates, the annual incidence of candidemia cases decreased from 31.5 per 100 000 births in 2009 to between 10.7 and 11.8 per 100 000 births per year between 2012 and 2015 ( Figure 1A ). Trends among infants were similar to trends in neonates; the incidence initially declined from 52.1 per 100 000 infants in 2009 to between 15.7 and 17.5 per 100 000 infants between 2012 and 2015 ( Figure 1B) . The incidence in noninfant children was 1.8 to 1.9 per 100 000 children between 2009 and 2010, an order of magnitude lower than that in infants. The incidence in this group declined steadily to 0.8 per 100 000 children in 2014 ( Figure 1C ) before rising slightly in 2015. Candidemia incidence trends varied according to site; the incidence in Baltimore in all pediatric age groups was higher than that in other sites across almost all time points. Although Atlanta, Portland, and Knoxville had fairly steady declines in the incidence of candidemia among noninfant children, an increased incidence occurred in Baltimore between 2013 and 2015.
Among the entire pediatric population, the crude incidence of candidemia among black patients was higher than that among nonblack patients. In 2015, the latest year with available data, the incidence was 3.3 per 100 000 among black patients compared with 0.6 per 100 000 among nonblack patients. The difference in incidences according to race was particularly notable among infants; the incidence among black infants was 26.5 per 100 000 compared with 5.8 per 100 000 among nonblack infants. Although the incidence among black infants declined along with that among nonblack infants, the incidence among black infants remained 2 to 4 times higher than that among nonblack infants during the study period. The overall incidence among male patients was the same as that for female patients (1.7 per 100 000), although male infants had a higher incidence (15.2 per 100 000) than female infants (11.9 per 100 000) in 2015.
Clinical Characteristics of Patients With Candidemia
Prematurity was the most common underlying condition (78%) among neonatal cases (Table 1) ; the median gestational age at birth among prematurely born neonates was 25 weeks (IQR: [24] [25] [26] . Nearly all of the premature neonates had a very low birth weight (1000-1500 g) or extremely low birth weight (<1000 g). Surgery in the 90 days before diagnosis was the most common (38%) underlying condition among nonneonate infants with candidemia; abdominal surgery was the most common type of surgery. For noninfant children, malignancy was the most common underlying condition (28%); hematologic malignancy accounted for half of these cases. Twentythree percent of noninfant children with candidemia had neutropenia at the time of diagnosis. Eighty-eight percent of all children with a case of candidemia had a CVC in place at the time of their diagnosis, and 63% had received total parenteral nutrition, including 76% of neonates and 83% of nonneonate infants. Ninety-nine percent of neonates and 83% of nonneonate infants were in the ICU at the time of their candidemia diagnosis, compared with 48% of the noninfant children at the time of candidemia diagnosis.
A previous episode of candidemia had occurred in 13% of nonneonate infants and in 20% of noninfant children with candidemia. The median time between candidemia episodes was 224 days (range, 31-2217 days). The median times from hospital admission (or from birth for neonates) to the first positive culture result were 11 days (IQR, 7-15.5 days) among neonates, 34 days (IQR, 9-59 days) among nonneonate infants, and 5 days (0-20 days) among noninfant children. Approximately 20% of all children had received antifungal medication, primarily fluconazole, in the 14 days before their blood was cultured, including 20% of neonates, 28% of nonneonate infants, and 18% of noninfant children with candidemia. After positive Candida culture results, almost all (97%) of the patients with candidemia received antifungal therapy. Amphotericin B was the most common antifungal agent used in neonates (80%) and nonneonatal infants (67%). Among noninfant children, fluconazole (66%) and echinocandins (44%) were used most commonly. Overall, the 30-day all-cause mortality rate was 13%; this rate was highest in neonates (16%) and lowest among noninfant children (11%), although this difference was not statistically significant (odds ratio, 0.67 [95% confidence interval, 0.32-1.42]).
Candida Species Distribution and Antifungal Resistance
Candida albicans was the most common species among neonatal cases (68%). Although C albicans was the single-most common species among cases in nonneonate infants and noninfant children, non-albicans Candida species predominated in both groups (>60% in both groups) ( Table 2) . Candida parapsilosis was the most common non-albicans Candida (NAC) species isolated in all age groups (neonates, 14%; nonneonate infants, 37%; noninfant children, 21%). C glabrata accounted for 8% to 9% of the isolates found among all pediatric age groups. We found no significant changes in species distribution between 2009 and 2015 for the overall pediatric population (Figure 2 ) or for each of the 3 age groups individually (data not shown).
Resistance to fluconazole or echinocandins was rare among all age groups (Table 2) . Fluconazole-resistant C albicans was seen among 1.6% of the isolates from neonates, 5% of the isolates from nonneonate infants, and 0% of the isolates from noninfant children. One echinocandin-resistant C albicans isolate from a child was identified. The only resistance observed among C parapsilosis isolates was a fluconazole-resistant isolate found in a child. No fluconazole or echinocandin resistance was identified among C glabrata isolates from neonates or nonneonate infants, and in noninfant children, 1 fluconazole-resistant and 1 echinocandin-resistant C glabrata isolate was found. Also found was 1 echinocandin-resistant C krusei isolate from a nonneonate infant.
DISCUSSION
In this report we describe the findings of prospective active population-based surveillance for candidemia in children conducted from 2009 to 2015 in 4 locations in the United States. The rates of candidemia among neonates were the highest, whereas the annual incidence in children was the lowest (~1 per 100 000 children) of any age group, including adults (~10-14 per 100 000 adults) [10] ; the incidence rates for infants were more than 10 times higher than those for noninfant children (~15 per 100 000 among infants, 1 per 100 000 among noninfant children). We found no consistent increases in NAC species in the overall pediatric population or in any pediatric age group, and the frequency of Candida isolates with resistance to antifungal agents was low among all age groups.
Our data are consistent with those published using the CDC National Healthcare Safety Network (NHSN) and its predecessor, the National Nosocomial Infections Surveillance System (NNIS), which revealed a decline in neonatal candidemia incidence rates between 1999 and 2009 [18, 19] . Although the incidence rates in the NHSN and NNIS are not directly comparable to those in this candidemia surveillance program because of differences in methodology and data sources, the overall trends can be compared. We found similar declines in incidence of candidemia between 2009 and 2011 among neonates and infants. Several factors might account for this decrease, including improvements in CVC insertion and care practices, the use of antifungal prophylaxis or empiric antifungal treatment, changes in underlying host risk factors, and changes in disease reporting. Several previous studies found declines in Table 2 central-line-associated Candida bloodstream infection rates after the institution of preventive strategies such as CVC care bundles and checklists in NICUs [20] [21] [22] [23] and declines in candidemia rates with the use of antifungal prophylaxis [24] [25] [26] [27] .
Although an initial decline occurred between 2009 and 2011, candidemia rates for neonates and infants remained stable between 2012 and 2015. This result mirrors trends in candidemia incidence among adults ≥65 years of age in the United States [10] , with a steady incidence of ~25 cases per 100 000 population between 2012 and 2015, after declines through 2012. Reasons for the lack of further declines in the neonatal and infant populations deserve further exploration. Because some infections are thought to be a result of translocation of Candida from the gastrointestinal tract (which would not be affected by catheter care), a reduction in central line use and catheter care might prevent only a proportion of candidemia cases. In fact, declines among adults have been found in CVC-related candidemia, whereas the rates of candidemia not associated with a CVC remained stable [10] . A similar trend of declines in CVC-related candidemia were seen in the overall pediatric population in this study, whereas the rates of candidemia not associated with a CVC remained stable (data not shown). Another possible explanation is changes in the adoption of antifungal prophylaxis practices. In a 2004 survey of perinatal physician practices, 34% of providers who cared for very low birth weight infants reported antifungal prophylaxis use [28] . Antifungal prophylaxis has likely increased as a result of the 2009 and 2016 Infectious Diseases Society of America recommendations and additional data from randomized controlled trials that revealed a benefit from antifungal prophylaxis [26, 27] . The adoption of antifungal prophylaxis guidelines might have contributed to a decline in candidemia incidence, but some infections continue to occur despite the use of prophylaxis. New prevention strategies might be needed to further reduce the incidence of candidemia among neonates and infants.
We observed, and were not surprised by, intersite variability in the incidence of candidemia. Variations in the underlying populations according to race, socioeconomic status, and frequency of risk factors and in clinical practice such as the use of antibiotics, antifungal prophylaxis, and infection control might contribute to differences in incidence rates reported from each site [29] . We found that black race was associated with an increased rate of disease incidence in all pediatric age groups. Racial differences in neonates have been linked to lower socioeconomic status and lack of prenatal care, both of which increase the risk for prematurity and low birth weight, which in turn are known risk factors for candidemia [30, 31] . Causes for the persistence of racial disparities in the pediatric population might be multifactorial and explained partly by the prevalence of underlying conditions that differ according to race, similar to black adults who are at increased risk for diabetes, renal disease, and other medical conditions that increase their risk for candidemia.
With more the widespread use of fluconazole prophylaxis, concerns exists over potential increases in nonsusceptible NAC species and the development of antifungal drug resistance; however, our data did not support these concerns [32] [33] [34] . Several neonatal and pediatric epidemiologic studies have found increases in NAC species since the 1990s [35] [36] [37] [38] , although numerous surveillance studies in the general population have found no association between fluconazole use and an increase in NAC species [34, [39] [40] [41] . We found no consistent increase in species-specific incidence in NAC species, and rates of in vitro antifungal resistance remained low, similar to the results of some European and Latin American surveillance studies [42] [43] [44] . However, the extent to which fluconazole prophylaxis practices have been adopted at our surveillance sites is not known. In our study, C parapsilosis remained the most common NAC species among infants and children, which is a finding that has been well documented already [3, 43, 45, 46] . The predominance of C parapsilosis infections has been attributed partially to its association with catheters, which results from its capacity to adhere to plastic and ability to thrive in parenteral nutrition. C parapsilosis has been associated also with outbreaks in NICUs caused by colonization present on the hands of healthcare workers [47] . Similar to a large multicenter prospective cohort study of children with candidemia [48] , we found that C glabrata accounted for 8% to 9% of isolates from all age groups, which indicates that C glabrata is not as infrequent in children as previously thought.
Resistance to antifungal agents increased with each increasing age group, which might be expected given that a patient is more likely to have been exposed to previous antifungal agents with increasing age. We found little fluconazole resistance in neonates but up to 5% in nonneonate infants (although this percentage represents only 1 of 20 C albicans isolates in this age group) and an even higher rate among noninfant children. It might be too soon to develop fluconazole resistance in the neonatal period, even if exposed to fluconazole prophylaxis during this time. Fluconazole resistance in the older age groups should be monitored closely to determine if fluconazole prophylaxis used in neonates results in increased resistance rates later in life. Rates of echinocandin resistance are increasing among Candida isolates found in adults; up to 12% of C glabrata isolates obtained through this candidemia surveillance initiative in 2014 were found to be nonsusceptible to echinocandins [49] . However, in the pediatric population in this study, only 3 echinocandin-resistant isolates were identified, which might be explained partially by C glabrata being less common in children and echinocandin use infrequent in pediatric populations [9] . With more safety data on the use of echinocandins in children, the use of these drugs is likely to increase in the pediatric population and might affect disease epidemiology.
Classic risk factors for neonatal candidiasis were common in the neonates included in this analysis, including premature birth and ICU admission. In our analysis, Hematologic malignancy was the most common underlying condition among noninfant children with candidemia. Previous studies documented the 1-year incidence of invasive fungal diseases (IFDs) among pediatric oncology patients and hematopoietic cell transplant (HCT) recipients to be as high as 13% to 20% and the mortality rate to be 58% to 83% [50] . Infections with Candida species are the most common IFDs seen in children during the neutropenic period immediately after an HCT. Antifungal prophylaxis is currently recommended for pediatric patients who are undergoing chemotherapy to treat certain hematologic malignancies and patients undergoing any form of HCT [14, 50] . Fluconazole is the most widely used agent [51] , but as more safety data become available, echinocandins can be used also. The effect of IFD prophylaxis on the incidence of candidemia in children with a malignancy needs further study.
Having received broad-spectrum antibiotics is a well-known risk factor for candidemia [5] . Sixty-two percent of cases received systemic antibiotics in the 14 days before candidemia. Although the appropriateness of the antibiotics given could not be assessed, this finding underscores the importance of antibiotic stewardship as a patient safety intervention to prevent adverse outcomes, such as invasive candidiasis, especially in highly vulnerable pediatric populations [52] .
Our study had several limitations. It was conducted in 4 US locations, and our results might not be generalizable to the entire US population; however, the geographic and demographic diversity of the sites and the large population under surveillance provide the most comprehensive population-based incidence estimates in the United States. Information on antifungal prophylaxis practices for neonates and children with a hematologic malignancy in hospitals participating in the surveillance system were not available for us to measure any effect of antifungal prophylaxis on incidence rates.
The clinical characteristics, species distribution, and antifungal-susceptibility patterns in our study are consistent with other published data and indicate no significant increase in risk of NAC infection or antifungal drug resistance among children. Additional studies are needed to evaluate the reason for the observed trends in incidence and interventions to further prevent candidemia infections in the pediatric population.
